Cepheid (CPHD) PT Raised to $72 at MKM Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Wedbush Cuts Price Target to $66 on Cepheid (CPHD) Following 2Q15
July 24, 2015 10:13 AM EDTWedbush reiterated an Outperform rating on Cepheid (NASDAQ: CPHD), and cut the price target to $66.00 (from $67.00), following 2Q15 results. CPHD reported 2Q15 sales of $133 MM compared to $131 MM estimates. Reported GAAP EPS was ($0.23), compared with consensus EPS loss of ($0.21).
Analyst Zarak Khurshid commented,... More
Needham & Company Raises Price Target to $70 on Cepheid (CPHD) Following 2Q15
July 24, 2015 7:34 AM EDTNeedham & Company reiterated a Buy rating on Cepheid (NASDAQ: CPHD), and raised the price target to $70.00 (from $66.00), following 2Q15 results. Revenue was $132.5M vs. consensus of $130.5M. Non-GAAP EPS was reported at ($0.23) vs. consensus of ($0.21).
Analyst Mike Matson commented, "CPHD's 2Q15 revenue beat... More
UPDATE: Evercore ISI Downgrades Cepheid (CPHD) to Sell; Analyst Sees Risk of Multiple Compression
July 24, 2015 6:46 AM EDT(Updated - July 24, 2015 8:28 AM EDT)
Evercore ISI downgraded Cepheid (NASDAQ: CPHD) from Hold to Sell with a price target of $53.50. Analyst Vijay Kumar noted a 42% rally since April and warned slowing growth and Q4 risk could lead to multiple compression.
"Shares of CPHD have rallied ~42% since reporting earnings on 4/23 vs. the S&P 500 at ~12%, largely due to strength in 1Q commercial clinical revenues, optimism around new product pipeline... More
Cepheid (CPHD) Tops Q2 EPS by 15c
July 23, 2015 4:41 PM EDTCepheid (NASDAQ: CPHD) reported Q2 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $132.5 million versus the consensus estimate of $130.7 million.
For earnings history and earnings-related data on Cepheid (CPHD) click here.
... More